Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.44 |
| ▸ | NGFR | P08138 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9314516 | 0.83 | KDM4E (0.60) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL30403281 | 0.83 | KDM4E (0.60) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL1144884 | 0.83 | KDM4E (0.60) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL6240318 | 0.83 | KDM4E (0.60) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL2015560 | 0.82 | KDM4E (0.55) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL30310573 | 0.82 | KDM4E (0.59) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL3110626 | 0.82 | KDM4E (0.59) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL11744575 | 0.80 | KDM4E (0.51) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL4374371 | 0.78 | KDM4E (0.55) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL913914 | 0.78 | FLT3 (0.68) | KDM4EHPGDALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0162695-B1 | 6-OXYGENATED-1,3,,4,5-TETRAHYDROBENZ(CD)INDOL-4-AMINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-01-17 | — | — | EP | disclosed |
| EP-0162695-A1 | 6-Oxygenated-1,3,,4,5-Tetrahydrobenz(cd)indol-4-amines | SMITHKLINE BEECHAM CORPORATION (US) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | KDM4E 2055/4885HPGD 348/4885ALDH1A1 822/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | KDM4E 1070/4885HPGD 824/4885ALDH1A1 348/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | KDM4E 1506/4885HPGD 1830/4885ALDH1A1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.